CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have
solid tumors and/or lymphoma that did not respond to previous therapy.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)